2.39
price up icon4.82%   0.11
 
loading
Adagene Inc Adr stock is traded at $2.39, with a volume of 193.35K. It is up +4.82% in the last 24 hours and up +27.81% over the past month. Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
See More
Previous Close:
$2.28
Open:
$2.22
24h Volume:
193.35K
Relative Volume:
2.22
Market Cap:
$112.59M
Revenue:
$18.11M
Net Income/Loss:
$-18.95M
P/E Ratio:
-5.4629
EPS:
-0.4375
Net Cash Flow:
-
1W Performance:
+41.42%
1M Performance:
+27.81%
6M Performance:
+16.02%
1Y Performance:
-11.81%
1-Day Range:
Value
$2.22
$2.55
1-Week Range:
Value
$1.80
$2.55
52-Week Range:
Value
$1.325
$3.5807

Adagene Inc Adr Stock (ADAG) Company Profile

Name
Name
Adagene Inc Adr
Name
Phone
-
Name
Address
-
Name
Employee
138
Name
Twitter
Name
Next Earnings Date
2024-03-28
Name
Latest SEC Filings
Name
ADAG's Discussions on Twitter

Compare ADAG with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ADAG
Adagene Inc Adr
2.39 92.33M 18.11M -18.95M 0 -0.4375
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-06-25 Initiated Leerink Partners Outperform
Jan-31-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-25-21 Initiated China Renaissance Buy
Mar-08-21 Initiated Goldman Buy
Mar-08-21 Initiated Jefferies Buy
Mar-08-21 Initiated Morgan Stanley Overweight
View All

Adagene Inc Adr Stock (ADAG) Latest News

pulisher
Aug 19, 2025

What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser

Aug 19, 2025
pulisher
Aug 17, 2025

HC Wainwright Issues Pessimistic Forecast for Adagene (NASDAQ:ADAG) Stock Price - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

How to read the order book for Adagene Inc. Depositary Receipt2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Q3 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

H.C. Wainwright lowers Adagene stock price target to $7 on development path clarity - Investing.com

Aug 15, 2025
pulisher
Aug 14, 2025

Adagene's 22.4% Surge: Clinical Breakthroughs and Strategic Alliances Ignite Biotech Volatility - AInvest

Aug 14, 2025
pulisher
Aug 13, 2025

How institutional ownership impacts Adagene Inc. Depositary Receipt stockPortfolio Gains Report & Risk Controlled Daily Plans - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

What indicators show strength in Adagene Inc. Depositary ReceiptJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

Published on: 2025-08-12 20:31:18 - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

Aug 12, 2025
pulisher
Aug 12, 2025

Cancer Drug Breakthrough: Adagene's ADG126 Doubles Standard Survival Rate as Sanofi Backs Development - Stock Titan

Aug 12, 2025
pulisher
Aug 10, 2025

Is Adagene Inc. Depositary Receipt still worth holding after the dipFree Low Risk Picks for Daily Trading - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Why Adagene Inc. Depositary Receipt is moving todayStock Price Prediction Using AI Tools - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Q2 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World

Aug 09, 2025
pulisher
Aug 08, 2025

Using R and stats models for Adagene Inc. Depositary Receipt forecastingFree AI Forecast for Trending Stocks - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Adagene (NASDAQ:ADAG) Raised to “Strong-Buy” at Leerink Partnrs - Defense World

Aug 08, 2025
pulisher
Aug 08, 2025

Leerink Partners Begins Coverage on Adagene (NASDAQ:ADAG) - Defense World

Aug 08, 2025
pulisher
Aug 06, 2025

Leerink Partners initiates Adagene stock with Outperform rating on cancer drug potential - Investing.com India

Aug 06, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Adagene Inc. Depositary Receipt in the next 12 monthsAccelerated investment success - Jammu Links News

Aug 03, 2025
pulisher
Jul 29, 2025

Why did ADAG's Q4 2020 EPS miss forecasts drastically? - AInvest

Jul 29, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-28 00:29:47 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 16, 2025

Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic By Stocktwits - Investing.com India

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene advances muzastotug to phase 2 trial after FDA meeting By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene advances muzastotug to phase 2 trial after FDA meeting - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene's Cancer Drug Shows Breakthrough 29% Response Rate, FDA Fast-Tracks Phase 2 Trial - Stock Titan

Jul 15, 2025
pulisher
Jul 10, 2025

Adagene Inc. and ConjugateBio Inc. Partner to Develop Novel Antibody Drug Conjugate - MarketScreener

Jul 10, 2025
pulisher
Jul 09, 2025

Adagene to provide antibody to ConjugateBio for bispecific ADC development By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Adagene Partners With ConjugateBio to Develop ADC Programs - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene to provide antibody to ConjugateBio for bispecific ADC development - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene Enters $30B ADC Market Through Strategic ConjugateBio Partnership for Novel Cancer Therapeutics - Stock Titan

Jul 08, 2025
pulisher
Jul 02, 2025

Adagene Secures $25 Million Investment from Sanofi to Advance Cancer Therapies - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewswire

Jul 01, 2025
pulisher
Jul 01, 2025

Sanofi invests up to $25 million in Adagene, exercises third option By Investing.com - Investing.com

Jul 01, 2025
pulisher
Jun 24, 2025

Adagene (NASDAQ:ADAG) Trading 0.3% Higher – Here’s Why - Defense World

Jun 24, 2025
pulisher
Jun 14, 2025

Adagene to present new ADG126 clinical data at ASCO-GI - MSN

Jun 14, 2025
pulisher
Jun 03, 2025

Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama

Jun 02, 2025
pulisher
May 31, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World

May 31, 2025
pulisher
May 27, 2025

Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World

May 23, 2025
pulisher
May 22, 2025

Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks

May 22, 2025
pulisher
May 22, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire

May 22, 2025

Adagene Inc Adr Stock (ADAG) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):